SynthesisAustralasian journal on ageing2026
Prevalence of Benzodiazepine, Z-Drug and Melatonin Use in Australian Residential Aged Care Facilities: A Systematic Review and Meta-Analysis.
Synthesis in Australasian journal on ageing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesTo systematically examine the prevalence of, and factors associated with, benzodiazepine, Z-drug and melatonin use in Australian residential aged care facilities (RACFs).
methodsMEDLINE, Embase, CINAHL, PsycINFO, Scopus and International Pharmaceutical Abstracts were searched from January 2000 to February 2025 for studies reporting benzodiazepine, Z-drug and/or melatonin prevalence in Australian RACFs. Overall, regular and pro re nata (PRN) medication use was considered. Screening, data extraction and quality assessment were performed independently by two authors. The primary outcome was overall prevalence (regular and PRN) of benzodiazepines, Z-drugs and/or melatonin. Secondary outcomes included regular prevalence, PRN prevalence and medication class prevalence.
resultsFifty-two studies (n = 658,585 residents) were included. Overall prevalence of benzodiazepines and/or Z-drugs was 33% (95% confidence interval [CI]: 30.4%-34.7%, 30 studies) when assessed over periods from point prevalence to one-year prevalence. Prevalence was highest when assessed using prescribing (35%) rather than dispensing (32%) or administration (28%) data. Findings were similar when limited to studies published in the last 10 years (31%), studies of 100 or more residents (32%) and when excluding studies conducted in subsets of residents (33%). Benzodiazepine prevalence (35% [95% CI: 32.5%-36.9%], 24 studies) was higher than Z-drug prevalence (0.4% [95% CI: 0.1%-1.1%], three studies). No published studies reported melatonin prevalence, and unpublished regular prevalence ranged 1%-9% (four studies).
conclusionsOne in three Australian residents in RACFs use benzodiazepines and/or Z-drugs. Targeted interventions are needed to ensure their use is consistent with evidence-based practice and residents' clinical needs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.